Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spina…

Drug Manufacturers - General

US, Cambridge [HQ]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Biogen Inc.'s gradings, price targets and earnings estimates.

Earnings

See the historical earnings and what wall street analysts forecasted and
forecast for future earnings.

Reported

Past Estimate Consensus

Future Estimate Consensus

EPS Revenue EBITDA EBIT SGA

All monetary values are presented in USD ($). E stands for Estimate.
FY	EPS		Revenue [mil.]		Profit [mil.]		EBITDA [mil.]		EBIT [mil.]		Expenses · SGA [mil.]
		E		E		E		E		E		E
2014	7.8600	11.540	6,932	8,977	1,862	2,664	2,807	4,224	2,490	3,606	1,712	2,041
2015	12.4200	16.510	9,703	10,630	2,934	3,280	4,350	4,996	3,916	4,514	2,232	1,966
2016	15.3800	20.168	10,763	11,515	3,547	3,455	5,521	5,493	5,014	4,805	2,113	1,826
2017	16.9600	21.994	11,448	12,051	3,702	2,246	6,541	5,905	5,653	5,009	1,947	1,826
2018	11.9400	25.918	12,273	13,326	2,539	4,142	6,526	6,617	5,527	5,511	1,935	1,970
2019	21.6200	33.243	13,452	14,243	4,430	5,318	6,860	7,165	6,000	6,330	2,106	2,152
2020	31.4700	33.790	14,377	13,380	5,888	3,268	7,518	4,650	7,035	3,542	2,374	2,237
2021	24.8600	19.192	13,444	10,872	4,000	1,366	4,807	2,182	4,446	2,531	2,504	2,373
2022	10.4400	17.108	10,981	10,072	1,556	1,820	3,656	3,377	2,808	2,738	2,674	2,619
2023	20.9700	14.995	10,173	9,928	3,046	1,161	2,686	3,889	2,901	3,119	2,403	2,948
2024	8.0200	16.410	9,835	9,632	1,161	2,389	2,598	3,355	1,831	2,947	2,549	2,100
2025	-	16.926	-	9,543	-	2,084	-	3,324	-	2,919	-	2,081
2026	-	17.643	-	9,709	-	2.F12X/td>	-	2.F121/td>	-	2.F121	-	2.F121
2027	-	18.806	-	9,983	-	1.F13X/td>	-	1.F131/td>	-	1.F131	-	1.F131
2028	-	20.309	-	10,109	-	0.F14X/td>	-	0.F141/td>	-	0.F141	-	0.F141

Institutional Sentiment

Wall Street · Earnings · Institutional Sentiment

The institutional sentiment measures the direction of new stock gradings
and price targets while comparing them Year-over-Year. We've limited the grading institutes to those we see as top-tier and update this data every month.

Morgan Stanley

1Y Ago:

Overweight

Prev. Grade

Overweight

Nov. 6, 2024

Overweight

JP Morgan Chase

1Y Ago:

n/a

Prev. Grade

n/a

Latest

n/a

Citigroup

1Y Ago:

n/a

Prev. Grade

n/a

Latest

n/a

Overall Consensus

Here we aggregate the price targets and gradings of all IBs/AMCs/Brokerage firms inside our database to draw a bigger picture.

Grading Consensus

Click to each, to see the grade

Price Target Consensus

-59.512% $93.97 · MISS

Nov. 6, 2024

Price Then

$176.93

Price Target

$251.87

Price Now

$157.90